WHO pauses trial of hydroxychloroquine in COVID-19 patients due to safety concerns
GENEVA (Reuters) - The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.
Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The U.S. President has said he was taking the drug to help prevent infection.
“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” Tedros told an online briefing.
He said the other arms of the trial - a major international initiative to hold clinical tests of potential treatments for the virus - were continuing.
The WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.
Dr. Mike Ryan, head of the WHO emergencies programme, said the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution”.